New Data Show Patients Treated with First-in-Class TREMFYA ® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years
SPRING HOUSE, PENNSYLVANIA, June 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with TREMFYA® (guselkumab) achieved consistent, long-term efficacy through two years across the domains of active psoriatic arthritis (PsA) – including joint, skin, enthesitis,a dactylitis,b spinal pain and disease severityc endpoints – irrespective of baseline characteristics.1 Further analyses showed TREMFYA also provided patients with sustained improvements in measures of health-related quality of life (HRQoL), including fatigue, pain...
Source: Johnson and Johnson - June 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
New Data Show TREMFYA ® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
SPRING HOUSE, PENNSYLVANIA, May 18, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first results of the in vitro MODIF-Y studies, supporting a hypothesis that may differentiate the mechanism of first-in-class TREMFYA® (guselkumab) from risankizumab due to the ability of TREMFYA to bind to CD64 positive (CD64+) cells in addition to interleukin (IL)-23 — both of which are key components of the immune system. 1,2 These findings, which are being presented at the Society for Investigative Dermatology (SID) annual meeting May 18-21, 2022 in Portland, Oregon, demonstrate TREMFYA bind...
Source: Johnson and Johnson - May 18, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Could Herpes Viruses Help Drive Type 2 Diabetes?
Title: Could Herpes Viruses Help Drive Type 2 Diabetes?Category: Health NewsCreated: 5/17/2022 12:00:00 AMLast Editorial Review: 5/18/2022 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - May 18, 2022 Category: Endocrinology Source Type: news
STI: Three 'must-know' complications of sexually transmitted infections – expert
TWO of the most common sexually transmitted infections for women in the UK are chlamydia and gonorrhoea, closely followed by herpes. Sometimes symptomless, if left untreated, health complications can occur. (Source: Daily Express - Health)
Source: Daily Express - Health - May 15, 2022 Category: Consumer Health News Source Type: news
Shingles: Eating less acidic foods could help reduce symptoms – what to eat instead
SHINGLES is activated by the herpes zoster virus that lies dormant within the body following a chickenpox infection, usually caught in childhood. (Source: Daily Express - Health)
Source: Daily Express - Health - May 5, 2022 Category: Consumer Health News Source Type: news
Shingles Risk Increased For People Over 50 Who Had COVID, Study Says
cbsoptanon.onScriptsReady(function(cmp){cmp.ot.targetingAllowed(function(a){if(a) AnvatoPlayer("p25").init({"mcp":"cbs","width":"100%","height":"100%","video":"6228464","autoplay":false,"titleVisible":false,"accessKey":"EZqvRyKE7qmqDflDPXIw6U7kKZEA0Vx7","accessControl":{"preview":false},"pInstance":"p25","plugins":{"heartbeat":{"account":"cbslocal-global-unified","publisherId":"cbslocal","jobId":"sc_va","marketingCloudId":"823BA0335567497F7F000101@AdobeOrg","trackingServer":"cbsdigitalmedia.hb.omtrdc.net","customTrackingServer":"cbsdigitalmedia.d1.sc.omtrdc.net","chapterTracking":false,"version":"1.5","customMetadata":{"vi...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - April 20, 2022 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News COVID-19 Covid-19 Boston, MA Health Healthwatch Syndicated CBSN Boston Syndicated Local Coronavirus Dr. Mallika Marshall Shingles Source Type: news
Use of RZV in Immunocompromised Adults Aged > 19 Years Use of RZV in Immunocompromised Adults Aged > 19 Years
Recombinant zoster vaccine is the first herpes zoster vaccine approved for use in immunocompromised persons. Review its use in this population in this brief article.Morbidity & Mortality Weekly Report (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - April 11, 2022 Category: Transplant Surgery Tags: Public Health & Prevention Journal Article Source Type: news
Incidence of Herpes Zoster Up for ≥50s With COVID-19 Diagnosis
FRIDAY, April 8, 2022 -- For adults aged 50 years or older, those with a COVID-19 diagnosis have an increased risk for developing herpes zoster, according to a study published online March 9 in Open Forum Infectious Diseases.
Amit Bhavsar,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 8, 2022 Category: Pharmaceuticals Source Type: news
Shingles (Herpes Zoster)
Title: Shingles (Herpes Zoster)Category: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 4/8/2022 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - April 8, 2022 Category: Dermatology Source Type: news
New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA ® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatment History
SPRING HOUSE, PENNSYLVANIA, March 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced its first-in-class interleukin (IL)-23 inhibitor TREMFYA® (guselkumab) provided a consistent, high degree of durable skin clearance through five years in a majority of adult patients across broad subpopulations with moderate to severe plaque psoriasis (PsO) in the Phase 3 VOYAGE 1 and VOYAGE 2 clinical trials.1 A separate post hoc analysis of the VOYAGE studies showed TREMFYA provided high rates of efficacy and durability through five years and similar safety outcomes among patients with and without...
Source: Johnson and Johnson - March 25, 2022 Category: Pharmaceuticals Source Type: news
Janssen Initiates First-of-its-Kind Clinical Study to Bridge Critical Gaps in Care for People of Color with Moderate to Severe Plaque Psoriasis
HORSHAM, PENNSYLVANIA, March 22, 2022 – Psoriasis (PsO) can take a physical, psychological, and emotional toll on the more than 8 million Americans living with the disease; and for people of color, there are additional challenges due to limited medical research and education, as well as underrepresentation in clinical studies.1,2,3 This has led to a lack of data and barriers to optimal care for diverse patient populations.2 PsO may also present with less noticeable skin reddening on darker skin tones, which can make it harder for healthcare providers to identify and lead to misdiagnoses in people of color. To help addres...
Source: Johnson and Johnson - March 23, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Acute herpetic stomatitis: clinical manifestations, diagnostics and treatment strategies
Conclusion: Conclusions: The article presents clinical peculiarities of herpetic stomatitis depending on disease severity and course. Primary herpetic stomatitis appears as spherical clustered vesicles on the gingival and adjacent mucosa. Soon after eruption of elements of lesion they rupture forming painful halo like aphtae / ulcers. Typical symptoms are: pain from ruptured vesicles, lymphadenitis, fever etc. Early diagnosis of disease is important and treatment with antiviral medicaments can modify the course of the disease by reducing symptoms and potentially reducing recurrences. Management of acute herpetic stoma...
Source: Dental Technology Blog - March 1, 2022 Category: Dentistry Source Type: news
STI: Four warning signs of an infection with the herpes simplex virus – it has 'no cure'
GENITAL herpes is considered a "common" sexually transmitted infection . Triggered by the herpes simplex virus, here are the warning signs of the contagious condition. (Source: Daily Express - Health)
Source: Daily Express - Health - February 22, 2022 Category: Consumer Health News Source Type: news
Harnessing the Herpes Virus to Beat a Deadly Brain Cancer
New findings show a genetically modified herpes virus appears to deliver a "one-two punch" to the rare and deadly form of brain cancer that killed U.S. Sen. John McCain. (Source: WebMD Health)
Source: WebMD Health - February 8, 2022 Category: Consumer Health News Source Type: news
